Drug
DS-3201b
DS-3201b is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 33.3%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
200%(2 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
completed125%
terminated250%
active_not_recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_1
DS-3201b in Participants With Lymphomas
NCT02732275
terminatedphase_1
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
NCT03879798
terminatedphase_1
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
NCT03110354
completedphase_1
Study of Single-dose DS-3201b in Participants With Hepatic Impairment
NCT04276662
Clinical Trials (4)
Showing 4 of 4 trials
NCT02732275Phase 1
DS-3201b in Participants With Lymphomas
NCT03879798Phase 1
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
NCT03110354Phase 1
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
NCT04276662Phase 1
Study of Single-dose DS-3201b in Participants With Hepatic Impairment
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4